1. Home
  2. EDSA vs AURE Comparison

EDSA vs AURE Comparison

Compare EDSA & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • AURE
  • Stock Information
  • Founded
  • EDSA 2015
  • AURE 2018
  • Country
  • EDSA Canada
  • AURE Hong Kong
  • Employees
  • EDSA N/A
  • AURE N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • AURE Finance: Consumer Services
  • Sector
  • EDSA Health Care
  • AURE Finance
  • Exchange
  • EDSA Nasdaq
  • AURE Nasdaq
  • Market Cap
  • EDSA 18.6M
  • AURE 19.4M
  • IPO Year
  • EDSA N/A
  • AURE N/A
  • Fundamental
  • Price
  • EDSA $1.73
  • AURE $0.41
  • Analyst Decision
  • EDSA Strong Buy
  • AURE
  • Analyst Count
  • EDSA 2
  • AURE 0
  • Target Price
  • EDSA $13.00
  • AURE N/A
  • AVG Volume (30 Days)
  • EDSA 908.6K
  • AURE 197.7K
  • Earning Date
  • EDSA 12-12-2025
  • AURE 02-13-2026
  • Dividend Yield
  • EDSA N/A
  • AURE N/A
  • EPS Growth
  • EDSA N/A
  • AURE N/A
  • EPS
  • EDSA N/A
  • AURE N/A
  • Revenue
  • EDSA N/A
  • AURE $142,570.00
  • Revenue This Year
  • EDSA N/A
  • AURE N/A
  • Revenue Next Year
  • EDSA N/A
  • AURE N/A
  • P/E Ratio
  • EDSA N/A
  • AURE N/A
  • Revenue Growth
  • EDSA N/A
  • AURE N/A
  • 52 Week Low
  • EDSA $1.55
  • AURE $0.31
  • 52 Week High
  • EDSA $4.49
  • AURE $2.70
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 35.70
  • AURE N/A
  • Support Level
  • EDSA $1.69
  • AURE N/A
  • Resistance Level
  • EDSA $1.83
  • AURE N/A
  • Average True Range (ATR)
  • EDSA 0.15
  • AURE 0.00
  • MACD
  • EDSA -0.01
  • AURE 0.00
  • Stochastic Oscillator
  • EDSA 17.00
  • AURE 0.00

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: